9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
May 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” Testosterone significantly affects urination differences between male and female mice.
23 citations
,
May 1984 in “Journal of the American Geriatrics Society” Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
15 citations
,
June 2018 in “Food Reviews International” Pumpkin seed oil may improve prostate health, bladder control, and hair growth in men.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
224 citations
,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
91 citations
,
July 2004 in “Journal of Biological Chemistry” Overexpressing SSAT enzyme reduces prostate tumor growth in mice.
50 citations
,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
8 citations
,
August 2011 in “Journal of Medicinal Food” D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
20 citations
,
August 2020 in “Scientific Reports” Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.
6 citations
,
May 2022 in “Research and reports in urology” Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.
1 citations
,
June 2025 in “Scientific Reports” Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.
710 citations
,
May 2023 in “European Urology” Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.
417 citations
,
February 2004 in “The Journal of Clinical Endocrinology and Metabolism” Testosterone therapy increases bone density in older men with low testosterone levels.
403 citations
,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
92 citations
,
November 2003 in “The Journals of Gerontology” Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.
61 citations
,
May 2010 in “Integrative Cancer Therapies” There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
29 citations
,
July 2013 in “The Journal of Sexual Medicine” Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
29 citations
,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
25 citations
,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.